Literature DB >> 25087627

Use of a hexasubstituted benzene scaffold in the development of multivalent HIV-1 integrase inhibitors.

Wipa Tupchiangmai1, Saowanaporn Choksakulporn, Supinya Tewtrakul, Somsak Pianwanit, Yongsak Sritana-anant.   

Abstract

The highly directional hexasubstituted benzene moiety was used as the central scaffold to create new human immunodeficiency virus (HIV)-1 integrase inhibitors through the attachment of multiple active groups. A series of potential inhibitors having substituted polyhydroxylated mono, bis and tris-cinnamoyl derivatives connected on the scaffold were prepared through Claisen-Schmidt condensations with substituted benzaldehydes, followed by partial demethylation to uncover the active phenolic groups required for the interactions with the integrase enzyme active sites. Using a multiplate integration assay method, four compounds carrying at least two sets of interacting moieties were found to be relatively potent integrase inhibitors with IC50 values in the low micromolar range. The results confirmed that multiple polyhydroxylated groups were required on the platform in order to effectively interact with the enzyme. The results from molecular docking studies consistently complemented the experimental results and revealed the nature of the potential key binding interactions responsible for the apparent activity of the active compounds.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25087627     DOI: 10.1248/cpb.c14-00074

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN: 0009-2363            Impact factor:   1.645


  2 in total

1.  Unexpected Formation of Hexasubstituted Arenes through a 2-fold Palladium-Mediated Ligand Arylation.

Authors:  Corin C Wagen; Bryan T Ingoglia; Stephen L Buchwald
Journal:  J Org Chem       Date:  2019-09-25       Impact factor: 4.354

2.  Doxorubicin-conjugated dexamethasone induced MCF-7 apoptosis without entering the nucleus and able to overcome MDR-1-induced resistance.

Authors:  Kamontip Chaikomon; Supreecha Chattong; Theerasak Chaiya; Danai Tiwawech; Yongsak Sritana-Anant; Amornpun Sereemaspun; Krissanapong Manotham
Journal:  Drug Des Devel Ther       Date:  2018-08-01       Impact factor: 4.162

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.